Firas ZAHR

Dr. Firas ZAHR

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
FZFiras ZAHR
Firas ZAHR
HSHoward K. Song
Howard K. Song
SCScott M. Chadderdon
Scott M. Chadderdon
HGHemal Gada
Hemal Gada
MMMubashir Mumtaz
Mubashir Mumtaz
MLMartin B. Leon
Martin B. Leon

23 October 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
FZFiras ZAHR
Firas ZAHR
HSHoward K. Song
Howard K. Song
SCScott Chadderdon
Scott Chadderdon
HGHemal Gada
Hemal Gada
MMMubashir Mumtaz
Mubashir Mumtaz
MLMartin B. Leon
Martin B. Leon

1 April 2018 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
LJLee Joseph
Lee Joseph
MBMohammad Bashir
Mohammad Bashir
QXQun Xiang
Qun Xiang
BYBabatunde A. Yerokun
Babatunde A. Yerokun
RMRoland Albert Matsouaka
Roland Albert Matsouaka
FZFiras ZAHR
Firas ZAHR

29 August 2025 in European Heart Journal
Verified
Journal Article
Closed access
PLPhilipp Lurz
Philipp Lurz
RHRebecca T Hahn
Rebecca T Hahn
SKSusheel Kodali
Susheel Kodali
RMRaj Makkar
Raj Makkar
RSRahul P Sharma
Rahul P Sharma
VTVinod H Thourani
Vinod H Thourani
Background and Aims: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods: The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results: One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions: Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.

10 August 2022 in Structural Heart
Verified
Journal Article
Open access
SCScott M. Chadderdon
Scott M. Chadderdon
MEMackram F. Eleid
Mackram F. Eleid
JTJeremy J. Thaden
Jeremy J. Thaden
RMRaj Makkar
Raj Makkar
MNMamoo Nakamura
Mamoo Nakamura
FZFiras ZAHR
Firas ZAHR
Patients with severe symptomatic tricuspid regurgitation face a significant dilemma in treatment options, as the yearly mortality with medical therapy and the surgical mortality for tricuspid repair or replacement are high. Transcatheter edge-to-edge repair (TEER) for the tricuspid valve is becoming a viable option in patients, although procedural success is dependent on high-quality imaging. While transesophageal echocardiography remains the standard for tricuspid TEER procedures, intracardiac echocardiography (ICE) with three-dimensional (3D) multiplanar reconstruction (MPR) has many theoretical and practical advantages. The aim of this article was to describe the in vitro wet lab–based imaging work done to facilitate the best approach to 3D MPR ICE imaging and the procedural experience gained with 3D MPR ICE in tricuspid TEER procedures with the PASCAL device.

1 December 2008 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
FZFiras ZAHR
Firas ZAHR
YOYoshio Ootaki
Yoshio Ootaki
RSRandall Starling
Randall Starling
NSNicholas G. Smedira
Nicholas G. Smedira
MYMohamad Yamani
Mohamad Yamani
KFKiyotaka Fukamachi
Kiyotaka Fukamachi